Has Kalyanam Shivkumar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $41,092 in general payments to Kalyanam Shivkumar, MD across 36 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kalyanam Shivkumar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kalyanam Shivkumar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kalyanam Shivkumar, MD

Cardiovascular Disease · Los Angeles, CANPI 1144240748

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (40.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Biotronik Inc. accounts for 65.8% of it on its own, with 6 other manufacturers making up the rest. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,092in general payments, 2019–2025

Across 36 payments — averaging $1141.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biotronik Inc.$27K
Boston Scientific$8K
Pacira Pharmaceuticals Incorporated$3K
Medtronic$2K
Abbott$711
Ablacon, Inc.$183
plus $58 from 1 others

$2,874,139in ownership & investment interests, 2019–2025

Across 2 payments — averaging $1,437,070 each. An ownership or investment interest held by the physician or an immediate family member.

Anumana, Inc.$2.9M

What the payments were for

Consulting fees$5,87814%
Speaking & faculty fees$16,64541%
Grants$1470%
Travel & lodging$16,67941%
Food & beverage$1,6734%
Education$700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biotronik Inc.	8	$27,043
Boston Scientific	10	$8,381
Pacira Pharmaceuticals Incorporated	2	$2,546
Medtronic	2	$2,170
Abbott	11	$711
Ablacon, Inc.	1	$183
Biosense Webster, Inc.	2	$58

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rivacor 7 DR-T$14,541
Acticor 7 VR-T DX$14,541
Edora 8 DR-T$14,541
Solia$12,631
BioMonitor$12,631
Farapulse$5,604
EXPAREL$2,546
GENERAL - THERAPIES$2,500
Sentus$1,910
ENSITE$176
AVEIR$134

How this compares

$41,092 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$12,587

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Los Angeles

Cathleen Bairey-MerzLos Angeles$1.2M
Karol WatsonLos Angeles$553K
Jamil AboulhosnLos Angeles$423K
Darren BermanLos Angeles$392K
Arash NayeriLos Angeles$281K
Gregg FonarowLos Angeles$260K
Martha GulatiLos Angeles$141K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →